newsfilter
← Latest News
GlobeNewswire·

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

ERNA
  • Ernexa Therapeutics (NASDAQ: ERNA) announced a company presentation at the Cell & Gene Meeting on the Mesa on October 7, 2025, in Phoenix, Arizona, with a virtual livestream option.
  • The presentation, scheduled for 2:45 p.m., will highlight Ernexa's progress on scalable, allogeneic induced mesenchymal stem cell (iMSC) therapies for cancer & autoimmune disease.
  • The company's pipeline includes ERNA-101, a lead therapy targeting ovarian cancer to stimulate immune recognition, & ERNA-201, a therapy targeting inflammation for autoimmune conditions.
  • Both programs utilize proprietary synthetic iMSC technology derived from induced pluripotent stem cells (iPSCs) to provide off-the-shelf treatments without patient-specific harvesting.
  • Recent prior activities include a presentation on iPSC opportunities at the 5th Annual iPSC Drug Development Summit in Boston & new ERNA-101 data shared at the AACR Special Conference regarding restoring a hot immune microenvironment in ovarian cancer.
  • The Cell & Gene Meeting on the Mesa addresses commercialization challenges in the sector, covering topics such as clinical trial design, payment models, & supply chain platforms.